Table 3.
Use of Concurrent Medications Before, During, and After Omalizumab Usage for Patients Who Discontinued Omalizumab (n=433)
| Concurrent Medication | Before Omalizumab Use | During Omalizumab Use | After Omalizumab Use |
|---|---|---|---|
| SABA | 55.7% | 59.1% | 54.3% |
| ICS plus LABA | 67.0% | 61.9% | 59.6% |
| ICS | 33.5% | 34.2% | 28.9% |
| LAMA | 20.1% | 20.6% | 19.2% |
| Xanthine | 6.0% | 6.9% | 5.5% |
| LABA | 5.8% | 4.6% | 3.9% |
| LTRA | 39.7% | 31.0% | 26.3% |
| OCS | 59.1% | 48.7% | 44.8% |
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2-agonist.